A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia

Trial Profile

A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 08 Sep 2014 Results reported in Lancet Respiratory Medicine and presented at the 2014 International Congress of the European Respiratory Society (ERS).
    • 12 May 2014 According to AstraZeneca media release, results from this trial presented at the American Thoracic Society (ATS) 2014, on 19 May 2014.
    • 03 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top